Regeneron Pharmaceuticals price to free cash flow REGN

Market value divided by free cash flow over the last twelve months, since 2013.

Today, Oct 23, 2026: 22.0×
10-year median: 22.1×
Against its 10-year history: 50th; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.9× to 52.8×
Peer median: 27.7×

Regeneron Pharmaceuticals' price to free cash flow is 22.0× as of Oct 23, 2026.

That is below its ten-year median of 22.1×, close to the middle of its last ten years.

Over that time it ranged from 7.9× in Jun 2022 to 52.8× in Nov 2016.

The median for 10 biotech stocks of a similar size is 27.7×.

Price to free cash flow over time

median 22.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	22.0×	15.5×	22.8×
2025	19.5×	15.4×	22.9×
2024	22.8×	21.6×	39.7×
2023	20.8×	15.5×	23.5×
2022	15.5×	7.9×	16.4×
2021	12.6×	12.2×	42.9×
2020	32.6×	18.6×	42.5×
2019	20.5×	15.3×	28.6×
2018	24.1×	22.2×	35.9×
2017	49.2×	43.6×	49.2×
2016	46.2×	35.6×	81.3×
2015	89.7×	77.0×	260×
2014	78.2×	66.5×	100×
2013	92.6×	90.1×	136×

Against its peers

Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
REGNRegeneron Pharmaceuticals	22.0×
VRTXVertex Pharmaceuticals	35.0×
ONCBeOne Medicines	32.3×
ALNYAlnylam Pharmaceuticals	37.8×
UTHRUnited Therapeutics	23.1×
INCYIncyte	12.2×
EXELExelixis	13.6×
NBIXNeurocrine Biosciences	16.7×
HALOHalozyme Therapeutics	17.7×
TECHBIO-TECHNE	43.2×
RGENRepligen	89.2×
Peer median	27.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Regeneron Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.